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Abstract
Human cancer cell lines are an important resource for research and drug development. However, the available
annotations of cell lines are sparse, incomplete, and distributed in multiple repositories. Re-analyzing publicly available
raw RNA-Seq data, we determined the human leukocyte antigen (HLA) type and abundance, identified expressed
viruses and calculated gene expression of 1,082 cancer cell lines. Using the determined HLA types, public databases of
cell line mutations, and existing HLA binding prediction algorithms, we predicted antigenic mutations in each cell line.
We integrated the results into a comprehensive knowledgebase. Using the Django web framework, we provide an
interactive user interface with advanced search capabilities to find and explore cell lines and an application
programming interface to extract cell line information. The portal is available at http://celllines.tron-mainz.de.
Background
Cancer cell lines are important tools for cancer and
immunological research [1–3] and are thus used daily in
laboratories and manufacturing. While genomic and im-
munological characterization of these cell lines is essen-
tial, publicly available information is far from complete
and typical lab assays are expensive and laborious. Fur-
thermore, most annotations have not used ontologies or
controlled vocabularies. Thankfully, due to efforts made
by others, such as the Cancer Cell Line Encyclopedia
(CCLE) [4] and Klijn et al. [5], many cell lines have been
sequenced, mutations have been annotated, and raw
datasets made publicly available.
We have developed bioinformatics workflows capable of
using these datasets to further annotate each cell line, in-
cluding the cell line origin, 4-digit HLA types [6], gene
expression levels, expressed viruses, and mutations. Som-
atic tumor mutations that give rise to mutated antigens
presented on the cell surface (neo-epitopes) are potent
targets for cancer immunotherapy [1, 3]. The number
of neo-antigens are further associated with the overall
survival of cancer patients [7] and the clinical response
to CTLA-4 and PD-1 checkpoint blockade in melanoma
patients [8–10]. Here, we integrated the cell line-specific
mutation information with the determined cell line-
specific HLA types and HLA binding prediction algo-
rithms to generate a catalog of cell line-specific predicted
HLA Class I and Class II neo-antigens.
Not only are these underlying characterizations im-
portant, but also the ability to easily query them in an
effective user interface is similarly essential. For example,
easy identification of a cell line appropriate for a specific
experiment would be enabling, such as quickly filtering
for a cell line with a specific HLA type and a specific
gene expression. Here, we address these challenges by
re-analyzing RNA-Seq data of 1,082 cancer cell lines and
integrating all results and available annotation in a cen-
tralized cell line annotation database and user-friendly
interface, called the TRON Cell Line Portal (TCLP). To
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our knowledge, the TCLP is the largest catalog of cancer
cell line annotations integrating HLA type, HLA expres-
sion, predicted HLA Class I and Class II neo-epitopes,
virus, and gene expression.
Construction and content
All the datasets integrated into the TCLP are publically
available: we downloaded the raw data and meta-data an-
notations, assigned each sample name using a controlled
vocabulary (that is, tissue ontology) and processed the as-
sociated next generation sequencing (NGS) reads using a
computational workflow comprising gene expression ana-
lysis; virus identification; determination of HLA type and
HLA expression; neo-epitope prediction based on cell
line-specific nucleotide mutations, determined HLA type
and HLA binding prediction algorithms. The resultant
characterizations are loaded into a database, accessible
through a web-based user interface and API.
Datasets
RNA-Seq datasets
We integrated cancer cell line RNA-Seq data from two
sources: The Cancer Cell Line Encyclopedia (CCLE) and
Klijn et al. [5] (Table 1). CCLE sequenced the transcrip-
tomes of 781 cancer cell lines using 101 nt paired-end
sequencing on Illumina HiSeq2000 and HiSeq2500 instru-
ments (https://cghub.ucsc.edu/datasets/ccle.html). Using
the GeneTorrent client software (https://cghub.ucsc.edu/
software/downloads.html) and the dataset identifiers pro-
vided on CGHub, we downloaded aligned paired-end
RNA-Seq samples in the Binary Alignment/Map (BAM)
format [11]. Using the Picard BAM2FASTQ tool
(http://picard.sourceforge.net), we converted the down-
loaded BAM files to FASTQ for further processing.
Klijn et al. [5] analyzed the transcriptional landscape of
675 human cancer cell lines, using 75 nt paired-end se-
quencing on an Illumina HiSeq 2000 instrument. After
gaining access, we downloaded the raw RNA-Seq data in
FASTQ format from the European Genome-phenome
archive, accession EGAD00001000725 (https://www.ebi.a-
c.uk/ega/datasets/EGAD00001000725).Of the 675 cell
lines, 374 overlapped with the CCLE samples and thus we
only processed the unique 301 cancer cell lines.
Mutation and cell line information
We retrieved the cell line annotation, including name,
disease, tissue, and mutation information (timestamp
2012.05.07) from the Broad-Novartis Cancer Cell Line
Encyclopedia [4] website as well as from Supplementary
Data 3 in Klijn et al. [5] (Table 1).
Cell line naming
Sample naming is critical to limit confusion. We store
and present the cell line primary name and, following
the CCLE naming convention, strip the name of any
special characters and convert it to uppercase during
processing. To increase the usability of the advanced
search, we manually compared and mapped the tissue
annotations and disease terms to the corresponding
terms from the National Cancer Institute (NCI) The-
saurus (http://ncit.nci.nih.gov/).
Gene expression
The raw reads were aligned using the STAR algorithm
(version 2.3.0e) [12] to the human reference genome
(hg19), allowing a total of 2 % mismatches based on read
length within the matched sequence. Other settings of
STAR remained at default settings. Sequence reads in
the resultant alignment files are input into our RNA-Seq
analysis, intersected with a BED file containing exons
from the UCSC known genes reference table [13], and
assigned to the overlapping gene. To calculate gene-level
expression, an isoform-to-gene dictionary is used during
this process such that if one read overlaps with more
than one isoform of a gene, it is counted only once. If
the read-to-gene assignment is ambiguous, the count
values for the potential genes are all incremented inde-
pendently. After quantification, the read counts are then
normalized to reads per kilobase of exon per million
mapped reads (RPKM) [14].
Virus detection
Reads that did not map to the human genome were
aligned to a reference database containing 5,006 virus se-
quences retrieved from the NCBI Viral Genomes home-
page on 29 November 2013 (http://www.ncbi.nlm.nih.gov/
genome/viruses/). To detect expressed viruses using the
Table 1 External data processed and integrated into the cell line portal
Data type Source Number cell lines Reference
Cancer cell line RNA-Seq data (2 × 101 bp) CCLE 781 [4], https://cghub.ucsc.edu/datasets/ccle.html
Cancer cell line RNA-Seq data (2 × 75 bp) Klijn et al. 301 [5], https://www.ebi.ac.uk/ega/datasets/EGAD00001000725
Mutations CCLE 781 [4]
Mutations Klijn et al. 675 [5], Supplementary data 3
HLA Class I and Class II types Adams et al. 49 [16]
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RNA-Seq reads, we recorded the percentage of a virus
genome covered by uniquely mapped reads. Over all
virus genomes in all reported cell lines we calculated
the sum of the mean coverage and the double standard
deviation. We used a cutoff of 30 % genome coverage
for reliable detection of expressed viruses [Bukur et al.,
manuscript in preparation].
HLA types
We used seq2HLA v2.2 [6] to determine the 4-digit
HLA type from the RNA-Seq reads. seq2HLA produces
accurate 2-digit calls [15] and 4-digit calls [6]. Where
available, we also include the HLA typing data deter-
mined by Adams et al. [16] (Table 1), in which the HLA
Class I and Class II genotypes of the NCI-60 cell lines
were determined using sequence-based typing (SBT), a
standard assay for HLA typing involving a targeted PCR
amplification of genomic DNA in the HLA locus.
Neo-epitope catalog
Using the determined 4-digit HLA Class I alleles and
non-synonymous single nucleotide variants (nsSNVs),
cell line-specific HLA Class I neo-epitope candidates are
determined as described previously [6], with the excep-
tion of using NetMHCpan v2.8 [17] as HLA binding
prediction tool and using the percentile rank as measure
of the best epitope selection instead of IC50. Similarly,
we determine the HLA Class II neo-epitopes for these
nsSNVs using NetMHCIIpan v3.0 [18] and the cell line
HLA-DRB1 type. If a mutation gives rise to multiple
equally prioritized neo-antigens (that is, they have the
same minimal percentile rank), all results are reported.
Only predicted neo-antigens with a percentile rank less
than 32 are reported.
Data storage and web access
To store, integrate, display, and interrogate the data, we
developed a platform based on Django, a python web
framework (http://www.ncbi.nlm.nih.gov/genome/vi-
ruses/). Within Django, data tables are described in Py-
thon models that are database agnostic, allowing one to
run the system on, for example, SQLite or PostgreSQL.
For performance reasons, the TCLP runs on Post-
greSQL in conjunction with the webproxy NGINX and
memcache for caching web requests.
We designed several models that describe the different
data elements, describe their relationships and hold the
data. Within Django, apps divide functionally different
data models. In our design, the main separation is be-
tween the Core, Ontology, and Molecular apps. As the
name suggests, the Core app provides the core function-
ality of the platform and the associated models store the
basic sample information, including name and identifier.
The Ontology app holds the data for the ontology-based
annotation, including disease and tissue. The Molecular
app stores the somatic mutations, gene expression
values, and the sample HLA types.
Utility and discussion
Web portal
Using our pipeline (Fig. 1), we processed RNA-Seq data
from 1,082 human cancer cell lines, generating HLA
type and quantification, virus identification and gene ex-
pression, and retrieved cell line mutations [4, 5]. The
outcome of this pipeline is freely accessible in the TRON
Cell Line Portal at http://celllines.tron-mainz.de.
The user web interface offers two main views, the sam-
ple information page (Fig. 2a) and the advanced search
functionality (Fig. 2b). The sample information page pro-
vides information about the selected cell line. Through a
tab-based interface, tables display tissue and disease type,
all linked mutations, gene expression values, detected
HLA types, and virus expression. The second view pro-
vides advanced search functionality, allowing one to search
by a combination and exclusion of criteria. For example,
the portal can easily execute the following query: ‘Show
me all melanoma cell lines that are (i) HLA-A*02:01 posi-
tive, (ii) express EGFR, (iii) have a BRAF p.V600E muta-
tion, and (iv) are annotated as female’. Translating this in
the search form, we specify HLA type ‘A’ with allele ‘02:01’,
have mutated gene ‘BRAF_p.V600E’, have gene expressed
‘EGFR’ with RPKM from 1 to 100 RPKM, leaving the virus
name field empty and do a ‘ALL and fuzzy’ search on the
properties to find cell lines annotated as ‘Female’ and have
the keyword ‘Melanoma’ in their disease description
(Fig. 3a). The cell lines A375, RPMI7951, and WM115 are
returned (Fig. 3b). Alternatively, search criteria can also be
logically negated, for example, searching for all female
melanoma samples that do not have the HLA type
A*02:01.
In addition to the user interface, we provide an API based
on the Django REST Framework (http://www.django-rest-
framework.org/). This provides the user direct access to
underlying data models and bulk data retrieval. The user
interface relies on and interacts with this API; advanced
users can thus discover the available entry points or alterna-
tively browse the API page at http://celllines.tron-mainz.de/
api. Additional file 1 shows an example python script to re-
trieve data using this API.
HLA type and expression
Knowledge of a cell lines HLA type and HLA expression
is critical for immunologic and cancer research and thera-
peutic development. As an example, in cancer immuno-
therapy, when developing a vaccine targeting specific
mutations presented on a patients HLA allele [19], one
might want to use a cancer cell expressing HLA-A*02:01
to identify mutation bearing neo-epitopes presented on





Fig. 1 Data integration and computational workflow. RNA-Seq data from 1,083 human cancer cell lines is downloaded from CCLE and Genentech
(a) and mutation information for the cell lines is retrieved (b). The RNA-Seq reads are processed by our in-house pipeline (c), consisting of HLA
typing and quantification, virus identification, gene expression analysis, and neo-epitope prediction. These data are integrated using consistent cell
line names as primary identifier and annotate tissue and disease information using the onotology NCI Thesaurus (d). The results are freely accessible in
the TRON Cell Line Portal (e) at http://celllines.tron-mainz.de
Fig. 2 The TRON Cell Line portal (TCLP) offers two main views. a The sample information page provides the information of the selected cell line.
b The advanced search functionality allows the search by a combination and exclusion of criteria
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HLA [6] and test T-cell activity [20]. In addition, the HLA
type of a cell line can be regarded as a molecular identifier
[21] and thus HLA typing can be utilized as sample bar-
code to detect mislabeled or contaminated samples [6].
To our knowledge, this is the largest catalog of HLA
type and expression annotated cancer cell lines. Using
paired-end RNA-Seq samples from 1,082 cancer cell
lines, we determined the 4-digit HLA Class I and Class
II type and HLA expression using the tool seq2HLA
[6, 15]. When available, HLA typing data from litera-
ture are integrated. Figure 2a shows results for the
prostate adenocarcinoma cell line PC-3.The HLA Class
I type is HLA-A*24:01, HLA-A*01:01, HLA-B*13:02,
HLA-B*55:01, HLA-C*01:02, and HLA-C*06:02, con-
sistent with the sequence-based typing (SBT) from Ad-
ams et al. [16]. In case of HLA-C, the latter only
provides 2-digit types, whereas seq2HLA provides the
4-digit HLA type, which is necessary for applications,
such as HLA binding predictions [17]. Among HLA Class
I allele in PC-3 cells, HLA-A shows the highest (109
RPKM) and HLA-B the lowest expression (16 RPKM).
PC-3 expresses HLA Class II alleles at very low levels:
HLA-DRB1*13:01 could be correctly identified despite the
very small number of mapped reads (0.04 RPKM) while
no reads were associated with other HLA Class II alleles.
Detected viruses
Infections or contaminations of cell lines by viruses can
be determined by the presence of viral sequences. As an
example, Additional file 2: Figure S1 shows the report
for the liver carcinoma cell line PLC/PRF/5 including
the determined HLA type and the detected viruses.
Here, concordant to the information from the American
Type Culture Collection (ATCC), the Hepatitis B virus
(HBV) genome is reported. The coverage of above 90 %
shows that most of the HBV genome is expressed as
mRNA. HBV infection is related to the onset of hepato-
cellular carcinoma [22] and thus this cell line may act as
a model for this cancer entity in terms of HBV infection.
Additionally, the Human endogenous retrovirus K113
(HERV-K113) is reported, the only HERV (human en-
dogenous retrovirus) genome present in this database.
HERV-K113 is present in many human genomes and is
known to express mRNA and even proteins [23, 24].
In addition of identifying new or already known cancer-
related virus infections, contaminations can be detected.
We find evidence (90 % genome coverage) of murine type
c retrovirus in the transcriptome of the bladder urothelial
carcinoma cell line 253JBV, which might have confound-
ing effects on experiments [25].
Mutations
The portal integrates mutation information for the ana-
lyzed cell lines from CCLE [4] and Klijn et al. [5]. For each
mutation, annotations are displayed, such as the affected
gene, the position in the genome, the type (for example,
substitution), the effect (for example, missense or intron),
and the influence on the protein sequence (for example,
p.Y58F means, that the Tyrosine residue at position 58 is
substituted by a Phenylalanine). In addition, we provide
Fig. 3 Example search: (a) ‘Show me all melanoma cell lines, that (i) are HLA-A*02:01 positive, (ii) express EGFR (between 1 and 1000 RPKM), (iii)
have a BRAF p.V600E mutation and (iv) are derived from a female donor. b This search reveals three cell lines
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links to the webpage of this entry at the respective source,
CCLE or Genentech, and a link to the ‘Drug Gene Inter-
action Database’, which identifies relationships between
mutated genes and drugs [26].
Neo-epitope catalog
Using the determined HLA Class I and Class II types in
conjunction with the mutations enabled us to define a
catalog of HLA Class I and Class II neo-epitope candi-
dates. Figure 4 shows the neo-epitope catalog for colon
carcinoma cell line HCT116, sorted from strong to weak
binding. The columns 1 to 3 describe the mutation and
columns 4 to 7 show the HLA allele, the percentile rank,
the sequence, and the IC50 of the predicted strongest
binding neo-epitope, respectively. Columns 8 to 11 show
information for the corresponding wild-type sequence.
Such a list can be input for experiments searching for
tumor HLA-ligands. As an example, Bassani-Sternberg
et al. [27] recently eluted HLA ligands from HCT116
cells, followed by mass spectrometry profile, and found
several mutation-containing ligands, which are listed in
the neo-epitope catalog, such as QTDQMVFNTY with a
predicted strong binding affinity (rank: 0.01, IC50: 8 nM,
marked row in Fig. 4).
Gene expression
The TCLP allows searching for and listing gene expres-
sion values from a selected cell line. The table enables
the user to filter via the gene name or to define a RPKM
value range. The table dynamically changes its content
to display only the data fulfilling the given criteria. The
gene name is linked to the NCBI platform for additional
gene information. All expression data of the current cell
line can be downloaded via a download button at the
top of the table or through the corresponding API.
Conclusion
Cell lines are critical model systems but cell line annota-
tions have been heterogeneous and sparse. Here, we col-
lected and annotated existing public cell line information
with ontologies. With internally available computational
pipelines, we reprocessed public raw data, including RNA-
Seq datasets of 1,082 cancer cell lines, to generate novel
annotations including HLA type, HLA expression, HLA
Class I and Class II neo-epitope candidates, gene expres-
sion, and expressed viruses. Integrating the multiple anno-
tations in one platform with an interactive interface and
advanced search capabilities, researchers can effectively
identify cell lines for their experiments and targets for
therapeutic development.
Availability and requirements
The TRON Cell Line Portal is freely accessible at http://
celllines.tron-mainz.de.
Additional files
Additional file 1: ‘fetch_expression_data.py’ is an example python
script showing how to use the TCLP API programmatically. Example
calls how to retrieve gene expression and HLA type data. (PY 2 kb)
Additional file 2: Figure S1. Virus identification. HBV is expressed in
the liver carcinoma cell line PLC/PRF/5. (PPTX 180 kb)
Abbreviations
API: application programming interface; ATCC: American Type Culture
Collection; CCLE: Cancer Cell Line Encyclopedia; HBV: the Hepatitis B virus;
HLA: human leukocyte antigen; NCI: National Cancer Institute; NGS: next
Fig. 4 Neo-epitope catalog of HCT116. Columns 1 to 3 describe the mutation, columns 4 to 7 show the HLA allele, the percentile rank, the
sequence, and the IC50 of the predicted strongest binding neo-epitope, respectively. Columns 8 to 11 show information for the corresponding
wild-type sequence. The marked row is the neo-epitope eluted and identified by mass spectrometry [27]
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generation sequencing; RPKM: reads per kilobase of exon per million
mapped reads; SBT: sequence-based typings.
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